Efficacy and safety of esketamine for emergency endotracheal intubation in ICU patients: a double-blind, randomized controlled clinical trial.
Scientific Reports · 2025-02-19 · Randomised trial
Abstract
Emergency endotracheal intubation in critically ill patients are dangerous procedures with a greater risk of severe hypotension The efficacy and safety of esketamine with sympathoexcitatory effects for rapid sequence induction in critically ill patients remain unclear. In this prospective double-blinded randomized controlled trial, adult patients were randomly assigned to receive either esketamine or midazolam/sufentanil admixture for induction. The primary outcomes were the effects of induction with esketamine or midazolam/sufentanil admixture on hemodynamic responses (heart rate (HR) and mean arterial pressure (MAP) during and after induction). Secondary outcomes were the duration of ventilation support, length of intensive care unit (ICU) stay, 28-day mortality. We enrolled 80 patients, of whom 38 were assigned to the esketamine group and 42 to the midazolam/sufentanil admixture group. The MAP in group esketamine was significantly higher than that in group midazolam/sufentanil admixture during the induction, and at 1 min, 5 min and 10 min after intubation. No significant differences in HR between groups were observed. The duration of ventilation support [105.3 (interquartile range (IQR) 40.9 - 248.3) hours vs. 211.5 (IQR 122.1 - 542.1) hours, P = 0.002] and the length of ICU stay [7.0 (IQR 4.0 - 16.3) days vs. 15.0 (IQR 8.0 - 26.0) days, P = 0.002] were significantly decreased in group esketamine, compared to that in group midazolam/sufentanil admixture. In group esketamine, less norepinephrine [0.00 (IQR 0.00 - 0.10) µg/kg/min vs. 0.09 (IQR 0.00 - 0.29) µg/kg/min, P = 0.016] was needed. There was no significant difference in 28-day mortality between the two groups. No serious adverse events occurred. In conclusion, esketamine is a hemodynamically stable induction agent in critically ill patients, which could reduce the length of ICU stay and the duration of ventilation support.Trial registration: clinicaltrials.gov (19/07/2022; NCT05464979).
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Anaesthetics · Endotracheal intubation · Midazolam · Rapid sequence intubation · Sedatives & anxiolytics
Related articles
- A comparison of the effects of etomidate and midazolam on hospital length of stay in patients with suspected sepsis: a prospective, randomized study. (Ann Emerg Med, 2010)
- [Impact of Sfar experts' conference entitled "Modalities of sedation and/or analgesia in hospital setting"]. (Ann Fr Anesth Reanim, 2008)
- Anesthetic induction drugs during tracheal intubation in critically ill patients: a systematic review. (J Anesth, 2026)
- Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. (J Trauma, 2008)
- Is propofol an optimal agent for procedural sedation and rapid sequence intubation in the emergency department? (CJEM, 2001)
- Etomidate versus midazolam for out-of-hospital intubation: a prospective, randomized trial. (Ann Emerg Med, 2006)